Skip to content
Screener

Theravance Biopharma TBPH Business Segments — Operating Expenses

Similar metrics at other companies

Alumis Inc. logo
ALMSSingle Reportable — Operating Expenses
$100.15M-15.8%
Immunome logo
IMNMSingle Reportable — Operating Expenses
-$59.33M-24.7%
Dogwood Therapeutics logo
DWTXSingle Reportable — Operating Expenses
$5.08M+14.6%
SES AI logo
SESSingle Reportable — Operating Expenses
$19.08M-31.4%
Iovance Biotherapeutics, Inc. logo
IOVASingle Reportable — Operating Expenses
$103.03M-16.0%
Natural Grocers by Vitamin Cottage logo
NGVCSingle Reportable — Operating Expenses
$79M+0.9%

Other financials

Income statement

See full
Revenue$17.7M+15.0%
Operating income-$9.5M+34.3%
Net income-$4.9M+63.7%
EPS (diluted)-$0.10+63.0%

Balance sheet

See full
Cash & equivalents$288.1M+160%
Total debt$40.5M-15.9%
Total equity$290.6M+75.1%
Total assets$472.3M+37.5%

Cash flow

See full
Operating cash flow$73.3M+70.3%
CapEx$8.0K-95.8%
Free cash flow$59.6M+5,560%

Valuation

See full
Market cap$876.93M+53.9%
Enterprise value$629.34M+88.3%
P/E7.7×-36.1×
P/S+0.6×

Profitability

See full
Gross margin60.8%
Operating margin1.2%+0.6pp
Net margin104.3%+71.4pp
FCF margin221.9%+206pp

Returns & leverage

See full
Return on equity50.2%+36.2pp
Debt / equity0.1×-0.2×
Current ratio13.1×+8.4×

Where this comes from

Reported directly by Theravance Biopharma in its filing.

Tagged under the XBRL concept us-gaap:OperatingExpenses.

The source filing: Theravance Biopharma’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 9:00 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001104659-26-056760
(In thousands)Three Months Ended March 31, 2026Three Months Ended March 31, 2025
Share-based compensation3,4764,877
Total recurring operating expenses23,54929,822
Restructuring expenses (including share-based compensation)3,633
Total operating expenses27,18229,822
Loss from operations(9,483)(14,434)
Interest expense (non-cash)(643)
Interest and other income, net3,013939
Provision for income tax benefit1,537559

Item 1. Financial Statements (unaudited)

FAQ

What is Theravance Biopharma's business segments — operating expenses?
Theravance Biopharma (TBPH) reported business segments — operating expenses of $27.18M in Q1 2026.
How has Theravance Biopharma's business segments — operating expenses changed year-over-year?
Theravance Biopharma's business segments — operating expenses decreased by 8.9% year-over-year, from $29.82M to $27.18M.
What is the long-term trend for Theravance Biopharma's business segments — operating expenses?
Over 2 years (2023 to 2025), Theravance Biopharma's business segments — operating expenses has grown at a -1.1% compound annual growth rate (CAGR), from $113.46M to $111.07M.
What does business segments — operating expenses mean?
This represents the total aggregate costs incurred to operate the business, including research, marketing, and administrative functions. It is the primary metric for assessing the overall cost structure and operational efficiency of the organization.

Ask your AI about Theravance Biopharma's business segments — operating expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude